Page last updated: 2024-11-12

lipoxin a4 methyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lipoxin A4 methyl ester: attenuates morphine antinociceptive tolerance [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9969174
CHEBI ID197104
SCHEMBL ID23347492
MeSH IDM0575423

Synonyms (9)

Synonym
CHEBI:197104
methyl (5s,6r,7e,9e,11z,13e,15s)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoate
5(s),6(r)-lipoxin a4 methyl ester
97643-35-1
5(s),6(r),15(s)-trihete methyl ester
SCHEMBL23347492
5(s),6(r)-lxa4 methyl ester
lipoxin a4 methyl ester
AKOS040755015

Research Excerpts

Overview

Lipoxin A4 methyl ester (LXA4 ME) is an inflammation inhibitor that exhibits potent protective effects in experimental stroke models.

ExcerptReferenceRelevance
"Lipoxin A4 methyl ester (LXA4 ME), is a stable synthetic analog of lipoxin with anti-inflammatory properties."( Lipoxin A4 Methyl Ester Reduces Early Brain Injury by Inhibition of the Nuclear Factor Kappa B (NF-κB)-Dependent Matrix Metallopeptidase 9 (MMP-9) Pathway in a Rat Model of Intracerebral Hemorrhage.
Cui, J; Cui, Y; Gao, J; Song, Y; Wang, K; Yang, Y, 2019
)
2.68
"Lipoxin A4 methyl ester (LXA4 ME) is an inflammation inhibitor that exhibits potent protective effects in experimental stroke models."( Lipoxin A4 methyl ester alleviates vascular cognition impairment by regulating the expression of proteins related to autophagy and ER stress in the rat hippocampus.
Dong, Y; Fan, M; Jia, Y; Jin, W; Li, L; Lv, P; Meng, N; Wang, T; Xiao, Y; Xu, J, 2015
)
2.58

Toxicity

ExcerptReferenceRelevance
" Treatment emergent adverse events (TEAEs) were assessed for safety, the primary outcome."( Safety and Preliminary Efficacy of a Novel Host-Modulatory Therapy for Reducing Gingival Inflammation.
Chiu, CJ; Cugini, M; Floros, C; Hardt, M; Hasturk, H; Martins, M; Schulte, F; Sherzai, H; Van Dyke, T, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
lipoxinA nonclassic icosanoid and signalling molecule that has four conjugated double bonds and is derived from arachidonic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (71.43)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.44 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (14.29%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]